John A. Stalfort III - 30 Jun 2021 Form 3/A - Amendment Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director
Signature
/s/ Katherine Denby, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
30 Jun 2021
Net transactions value
$0
Form type
3/A - Amendment
Filing time
08 Jul 2021, 17:59:18 UTC
Date Of Original Report
30 Jun 2021
Next filing
08 Jul 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABOS Series B Preferred 30 Jun 2021 Common Stock 131,595 See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock will automatically convert into the same number of shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
F2 These shares were omitted from the reporting person's original Form 3.
F3 The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.